Key highlights
- Achieved an 82% objective response rate in 22 efficacy-evaluable patients with pancreatic ductal adenocarcinoma
- Reported an 88% progression-free survival rate at the nine-month mark
- Planned initiation of a registrational Phase 3 trial in first-line patients for early 2027
- Confirmed 100% disease control rate among patients treated with the combination therapy
- Maintained a strong safety profile with no dose-limiting toxicities or treatment-related withdrawals
Clinical Trial Outcomes and Efficacy
Tango Therapeutics presented updated clinical data at the European Society for Medical Oncology (ESMO) 2026 Congress, highlighting the performance of vopimetostat combined with Revolution Medicines' daraxonrasib. In a cohort of 22 efficacy-evaluable patients with second-line or third-line MTAP-deleted and RAS-mutant pancreatic ductal adenocarcinoma, the combination achieved an 82% objective response rate. Furthermore, the 9-month progression-free survival rate stood at 88%, while the median progression-free survival has not yet been reached. The study also demonstrated a 100% disease control rate, suggesting the regimen may provide durable stability for patients who have historically faced limited treatment options after initial chemotherapy failure.
Strategic Development and Phase 3 Planning
- Collaborated with the U.S. FDA to design a registrational Phase 3 trial for first-line pancreatic cancer patients
- Scheduled the initiation of the pivotal Phase 3 study for the first half of 2027
- Explored additional combinations of vopimetostat with RAS inhibitors in MTAP wild-type tumors
- Identified PRMT5 inhibition as a potential backbone for broader combination strategies in solid tumors
- Targeted heavily pretreated populations where more than half of participants received treatment as a third-line therapy
Executive Perspective on Treatment Potential
“It is encouraging to see that the clinical activity and tolerability observed in our initial June 2026 dataset has been confirmed with longer follow-up and in a larger patient population, affirming our belief that the response rate and durability observed with vopimetostat plus daraxonrasib surpass any published PDAC datasets, even in front-line settings.”
Financial Position and Operational Outlook
The clinical advancement is supported by a robust balance sheet. As of mid-2026, the company reported approximately $1.0 billion in cash and marketable securities, which management projects will fund operations into 2030. This liquidity follows a series of capital market activities, including a $600 million upsized public offering in June 2026 and a $400 million at-the-market equity offering program established in August 2026. With trailing twelve-month revenue of $62.38 million primarily from collaboration agreements, Tango is leveraging its capital to transition from early-stage clinical work to registrational trials without immediate financing pressure.
Down 13.5% since our story on 23 Oct: $27.93 when we broke it → $24.17 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $23.53 |
|---|---|
| 20 Oct | $25.25 |
| 21 Oct | $26.98 |
| 22 Oct | $27.93 |
| 23 Oct | $23.34 |
| 26 Oct | $22.20 |
| 27 Oct | $22.89 |
| 28 Oct | $22.23 |
| 29 Oct | $22.53 |
| 30 Oct | $22.72 |
| 2 Nov | $21.76 |
| 3 Nov | $23.17 |
| 4 Nov | $23.18 |
| 5 Nov | $20.87 |
| 6 Nov | $21.50 |
| 9 Nov | $22.74 |
| 10 Nov | $24.30 |
| 11 Nov | $25.73 |
| 12 Nov | $24.85 |
| 13 Nov | $25.50 |
| 16 Nov | $24.17 |
Targeted Oncology and Industry Context
Tango Therapeutics focuses on synthetic lethality, a drug development strategy that targets genetic vulnerabilities unique to cancer cells. Vopimetostat specifically targets PRMT5 in tumors with MTAP deletions, a genetic alteration found in approximately 10% to 15% of all human cancers. Pancreatic ductal adenocarcinoma remains one of the most aggressive malignancies with high unmet needs, as current standards of care often result in rapid progression. By combining PRMT5 inhibitors with RAS-targeted therapies, Tango aims to block two major oncogenic drivers simultaneously, a strategy that has shown increased potency and durability in recent clinical observations compared to monotherapy or traditional chemotherapy.
| Date | Announcement | Amount |
|---|---|---|
| 16 Oct 2026 | Announced presentation of Phase 1/2 vopimetostat combination data at ESMO Congress 2026Source: ir.tangotx.com | – |
| 11 Aug 2026 | Filed prospectus supplement for an expanded at-the-market equity offering program of up to $400 millionSource: ir.tangotx.com | $400.0 Million |
| 09 Jun 2026 | Announced pricing of upsized underwritten public offering of common stock and pre-funded warrantsSource: ir.tangotx.com | $600.0 Million |
| 08 Jun 2026 | Announced positive initial Phase 1/2 combination data of vopimetostat with daraxonrasib in pancreatic cancerSource: ir.tangotx.com | – |
| 21 Nov 2025 | Entered into an at-the-market sales agreement to offer up to $100 million of common stockSource: SEC filing | $100.0 Million |
| 23 Oct 2025 | Announced pricing of $225 million financing via underwritten offering and concurrent private placementSource: tangotx.gcs-web.com | $225.0 Million |
Management commentary
“Following discussions with the U.S. FDA, we are focused on initiating a planned registrational Phase 3 trial of vopimetostat with daraxonrasib in front-line patients with MTAP-deleted pancreatic cancer in the first half of 2027.”
| Share price | $27.93 |
|---|---|
| Market cap | $4.7B |
| Revenue (annual) | $62M |
| 1-month price change | +9.40% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Tango Therapeutics, Inc. announcing updated Phase 1/2 clinical results and development strategy for vopimetostat.
Track Tango Therapeutics, Inc. live
Get the next Tango Therapeutics, Inc. SEC filing seconds after it lands.